Cyclacel Pharmaceuticals, Inc.(CYCCP) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Cyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE As of September 30, 2024, cash equivalents totaled $3.0 million, compared to$3.4 million as of December 31, 2023. Net cash used in operating activities was $6.6 million for the nine months ended September 30, 2024 compared to$12.2 million for the same period of 2023. The Company estimates that its available cash will fund currently planned programs into the fourth quart ...